Bio-Techne Corporation has reported Q4 CY2025 results that exceeded Wall Street's revenue expectations, achieving an adjusted earnings per share (EPS) of $0.46, 5.8% above analyst consensus, despite total revenue remaining flat at $295.9 million. The company demonstrated resilience with an improved operating margin of 18.4% and significant growth in its diagnostics business, while also reducing bank debt by $40 million. Ongoing success in the Chinese market and consistent organic revenue expectations further support Bio-Techne's strategic growth initiatives.
“Bio-Techne · reported · Q4 CY2025 results · beating Wall Street’s revenue expectations”
“Bio-Techne · sales were · flat year on year · $295.9 million”
“Bio-Techne · its non-GAAP profit was · $0.46 per share · 5.8% above analysts’ consensus estimates”
“Bio-Techne · Adjusted EPS was · $0.46 · 5.8% beat”
“Bio-Techne · Adjusted EBITDA was · $103.4 million · 8.4% beat”
“Bio-Techne · Operating Margin was · 18.4% · up from 16% in the same quarter last year”
“Bio-Techne · Market Capitalization is · $10.7 billion”
“Bio-Techne · achieved growth in China · for three consecutive quarters”
“Bio-Techne · diagnostics business delivered · high single-digit growth”
“Bio-Techne Corp · reported · adjusted EPS · $0.46, up 10% year-over-year”
“Bio-Techne Corp · reported · GAAP EPS · $0.24, up from $0.22 in the prior year period”
“Bio-Techne Corp · reported · total revenue · $295.9 million, flat year-over-year on both an organic and reported basis”